Softhale N.V.
Softhale N.V. (Softhale) is a wholly owned subsidiary of invoX. It is a Belgian-based respiratory company focused on the development of pharmaceutical products delivered by their SMI device to the lungs.
Technology
Softhale is developing liquid-based, Soft Mist Inhaled (“SMI”) products with superior clinical performance based upon differentiated technology. A proprietary, propellant-free, purely mechanical device delivers medication to the lungs more effectively than other types of inhalers and in large markets including Asthma, COPD, and other lung indications.
Founders & Team
The founders out of Germany met in 2012 and started their conceptual work on a new generation Soft Mist Inhaler (SMI) which resulted in their 1st patent in 2013. Over the years the team grew with profound medical, pharmaceutical / chemical, medical device, and consumer products expertise.
Acquisition
On 22 March 2021, invoX entered into an agreement in relation to a 100% acquisition of Softhale.
invoX vision on Softhale
The following strategic significance is considered by the Board:
- Solidifies the Group’s leading position in the respiratory therapeutic area by offering the next general inhaler technology.
- Enhances the Group’s transformation from generics to innovation player by acquiring and fully controlling its own respiratory R&D capability.
- Accelerates the Group’s internationalization strategy by establishing a local hub in Europe as well as developing products with significant global market potential